FDA Approves 29 Novel Oncology Therapies in H1 2024, Bringing New Hope to Patients with Lung Cancer, Breast Cancer, and Other Major Cancers

Jul 19, 2024 23:59 CST Updated 23:59

AstraZeneca

Biopharmaceutical Manufacturer

Roche

Oncology Drug Research, Development, and Manufacturing

Merck Group

Pharmaceutical R&D Developer

Half of 2024 has passed in the blink of an eye. In these six months, there has been a surge in the launch of new anti-cancer drugs both in China and internationally, with the FDA approving a total of 29 new cancer therapies, includingTargeted therapy, immune checkpoint inhibitors, adoptive cell immunotherapyetc., covering common types of solid tumors and hematologic malignancies.

The Medical Department of Global Oncologists Network reviews the drug approval information from the official website of the U.S. FDA and the National Cancer Institute at mid-year and year-end each year, to compile and update all cancer-approved targeted drugs for everyone, bringing confidence in the fight against cancer. (The following information is for reference only; specific medication plans must follow medical advice. You can also call the Medical Department of Global Oncologists Network at 4006667998).

Summary of Drugs Approved by the U.S. FDA in the First Half of 2024

Non-Small Cell Lung Cancer

1. Non-Small Cell Lung Cancer - Tepotinib

Drug Name：Tepotinib (Tepotinib, Tepmetko）。

R&D Company：Merck & Co.

Time to Market：February 15, 2024。

Drug Introduction：On February 3, 2021, the FDA granted accelerated approval for Merck's Tepotinib (Tepmetko) to be marketed. On February 15, 2024, Tepotinib was officially approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 (MET ex14) skipping mutations. On March 25, 2020, Japan's Ministry of Health, Labour and Welfare was the first to approve it for marketing.Becoming the world's first approved oral MET inhibitor for the treatment of patients with advanced non-small cell lung cancer carrying MET gene mutationsRegardless of how many therapies patients have received in the past, Tepotinib has improved patient outcomes compared to currently available treatments.Read the original article for more details: Express | 43% response rate! New drug for lung cancer, FDA accelerates approval of tepotinib!

2. Non-Small Cell Lung Cancer - Alectinib

Drug Name：Alectinib (Alecinib, Alecensa, Alectinib).

R&D Company：Roche.

Time to Market：April 18, 2024.

Drug Introduction：Alectinib, a second-generation ALK inhibitor developed by the American pharmaceutical giant Roche, is known as the "most potent targeted drug for lung cancer" due to its stronger efficacy and powerful blood-brain barrier penetration. It has become the first-line treatment of choice for ALK-positive patients in China. In December 2015, Alectinib was first approved by the FDA as a treatment option following resistance to Crizotinib. In November 2017, the approval was expanded to include first-line treatment for untreated ALK-positive metastatic non-small cell lung cancer (NSCLC) patients. On April 18, 2024, based on the results of the ALINA trial, the U.S. Food and Drug Administration (FDA) approved Alectinib as adjuvant therapy for ALK-positive NSCLC patients.Read the original text for more details: Overview of Lung Cancer Targeted Drug Alectinib

3. Non-Small Cell Lung Cancer - Osimertinib

Drug Name：Osimertinib (Tagrisso, osimertinib, Tagrisso).

R&D Company：AstraZeneca.

Time to Market：February 16, 2024。

Drug Introduction：Osimertinib is an irreversible third-generation EGFR inhibitor (EGFR-TKI) developed by AstraZeneca, capable of overcoming the T790M resistance mutation. On March 30, 2017, the FDA officially approved osimertinib for the treatment of metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC) in patients whose disease has progressed during or after treatment with EGFR tyrosine kinase inhibitors (TKIs). On April 18, 2018, the FDA approved osimertinib as a first-line treatment for NSCLC with EGFR mutations (exon 19 deletions or exon 21 L858R mutations). On February 16, 2024, the U.S. FDA approved osimertinib in combination with platinum-based chemotherapy for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).Read the original text for more details: Overview of Lung Cancer Targeted Drug Osimertinib Information

4. Non-Small Cell Lung Cancer - Amivantamab

Drug Name：Johnson & Johnson.

R&D Company：Amivantamab-vmjw (Rybrevant, code name JNJ6372).

Time to Market：March 1, 2024.

Drug Introduction：Amivantamab, developed by Johnson & Johnson, is a fully human bispecific antibody targeting EGFR and MET receptors, which can inhibit tumor growth and lead to tumor cell death. On May 21, 2021, the FDA officially approved the marketing of amivantamab. This is the first targeted therapy for patients with EGFR exon 20 insertion mutation lung cancer, marking a significant advancement in medicine for these patients, and it has milestone significance! On March 1, 2024, the U.S. Food and Drug Administration (FDA) approved amivantamab in combination with chemotherapy (carboplatin + pemetrexed) as a first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.Read the original article for more details: Milestone! FDA Announces Major Approval: Rybrevant, the First Targeted Drug for Non-Small Cell Lung Cancer EGFR 20ins, Hits the Market

Small Cell Lung Cancer

Taladotinib

Drug Name：Tarlatamab (Tarlatamab, tarlatamab-dlle).

R&D Company：Amgen Inc.

Time to Market：May 16, 2024.

Drug Introduction：Tarlatamab (DLL3/CD3 Bispecific Antibody) is a first-in-class DLL3-targeted bispecific T-cell engager (BiTE)® developed by Amgen. On May 16, 2024, it received accelerated approval from the U.S. FDA for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed during or after platinum-based chemotherapy.Tarlatamab is the first and only approved DLL3-targeted bispecific T-cell engager therapy for the treatment of aggressive lung cancer., is an important milestone in the field of small cell lung cancer treatment!Read the original article for more details: FDA Finally Approves! Small Cell Lung Cancer Welcomes Groundbreaking New Drug Tarlatamab! Survival Extended by 2 Times! More Therapies Strike Lung Cancer

Colorectal Cancer

Adagrasib

Drug Name：Adagrasib (Adagrasib, MRTX849).

R&D Company：Mirati Therapeutics（MRTX）。

Time to Market：June 22, 2024.

Drug Introduction：Adagrasib (MRTX849), an orally available, potent, and selective small-molecule inhibitor of KRAS G12C mutant, was granted accelerated approval by the U.S. Food and Drug Administration on June 21, 2024, in combination with cetuximab for the treatment of adult patients with locally advanced or metastatic colorectal cancer (CRC) harboring the KRAS G12C mutation, who have previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

Pancreatic Cancer

Irinotecan Liposome Injection

Drug Name：Irinotecan Liposome Injection (Onivyde®, Ipsen Biopharmaceuticals, Inc).

R&D Company：PharmaEngine.

Time to Market：February 13, 2024.

Drug Introduction：Irinotecan Liposome Injection (Onivyde®) is a topoisomerase inhibitor. Irinotecan is encapsulated in tiny fat particles called "liposomes," which accumulate in tumors and slowly release over time, blocking topoisomerase I, thereby preventing cancer cells from proliferating and eventually leading to their death. On February 13, 2024, the U.S. FDA approved Irinotecan Liposome Injection in combination with the NALIRIFOX regimen (oxaliplatin, fluorouracil, and leucovorin) for first-line treatment of metastatic pancreatic adenocarcinoma.

Esophageal Cancer

Tislelizumab

Drug Name：Tislelizumab (tislelizumab-jsgr, English trade name: TEVIMBRA®, Chinese trade name: 百泽安®).

R&D Company：BeiGene.

Time to Market：March 14, 2024.

Drug Introduction：Tislelizumab is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody independently developed in China. On March 14, 2024, the U.S. FDA approved tislelizumab as a monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who have previously received systemic chemotherapy not including PD-(L)1 inhibitors. It isChina’s First Successful "Going Overseas" PD-1 Inhibitor!Read the original article for more details: Major Good News: Tislelizumab, China's First Self-Developed PD-1 Inhibitor, Approved for Marketing by the U.S. FDA

Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer

Somatropin Injection

Drug Name：Somiromab Injection (ELAHERE®, HDM2002, mirvetuximab soravtansine-gynx).

R&D Company：Huadong Medicine.

Time to Market：March 22, 2024.

Drug Introduction：Mirvetuximab soravtansine was granted accelerated approval by the U.S. FDA in November 2022 for the treatment of folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer that has been treated with 1-3 prior systemic regimens. The drug's marketing application was accepted by China's CDE in October 2023 and included in the priority review directory. On March 22, 2024, it received full approval from the U.S. FDA for the treatment of adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.Somiromab is the world's first ADC drug targeting folate receptor α-positive ovarian cancer, and it is also the first and only ADC drug (i.e., antibody-drug conjugate) approved by the U.S. FDA for the treatment of this type of malignant tumor., which has opened a new direction for the treatment of ovarian cancer, also marks that platinum-resistant recurrent ovarian cancer has entered the era of ADC treatment.

Cervical Cancer

1. Cervical Cancer - Pembrolizumab

Drug Name：Pembrolizumab (Paimu monoclonal antibody, pembrolizumab, Keytruda).

R&D Company：Merck & Co., Inc. (MSD).

Time to Market：January 12, 2024.

Drug Introduction：Pembrolizumab is a重磅 anti-PD-1 inhibitor developed by MSD (Merck & Co.), and alsoChina's First Approved PD-1 Inhibitor, which helps discover and combat tumor cells by enhancing the capabilities of the human immune system.On January 12, 2024, the U.S. FDA approved pembrolizumab for patients with stage III-IVA cervical cancer. Notably,Keytruda is the first and only approved anti-PD-1 therapy to be used in combination with chemoradiotherapy for the treatment of this type of cervical cancer.。

2. Cervical Cancer - Tislelizumab

Drug Name：Tisotumab vedotin-tftv (Tivdak).

R&D Company：Seagen, Genmab.

Time to Market：April 29, 2024.

Drug Introduction：Tivatuzumab is an antibody-drug conjugate (ADC) composed of a human monoclonal antibody targeting tissue factor (TF) developed by Genmab, combined with Seagen’s ADC technology. On April 29, 2024, it received approval from the U.S. FDA for the treatment of recurrent or metastatic cervical cancer that has progressed during or after chemotherapy. Notably, the drug had already received accelerated approval from the FDA on September 20, 2021.Tisotumab is the first for cervical cancerOne is also the goalThe only antibody-drug conjugate (ADC) previously approved。Milestone! The First ADC Therapy for Advanced Cervical Cancer Has Arrived! Tivdak Receives FDA Approval for Market Launch

Endometrial Cancer

1. Endometrial Cancer - Durvalumab

Drug Name：Durvalumab (Trade name: Imfinzi®).

R&D Company：AstraZeneca.

Time to Market：June 14, 2024.

Drug Introduction：On June 14, 2024, the U.S. FDA approved a new indication for durvalumab, to be used in combination with carboplatin and paclitaxel, followed by durvalumab monotherapy for adult patients with mismatch repair-deficient (dMMR) primary advanced or recurrent endometrial cancer. Notably,Durvalumab is the first PD-L1 monoclonal antibody drug approved for endometrial cancer.

2. Endometrial Cancer - Pembrolizumab

Drug Name：Pembrolizumab (Pembro, pembrolizumab, Keytruda).

R&D Company：Merck & Co., Inc. (MSD).

Time to Market：June 17, 2024.

Drug Introduction：On June 17, 2024, the US FDA approved pembrolizumab alone or in combination with chemotherapy (carboplatin and paclitaxel) for the treatment of adult patients with primary advanced or recurrent endometrial cancer.

Melanoma

lifileucel

Drug Name：lifileucel（LN-144，Amtagvi）。

R&D Company：Iovance Biotherapeutics.

Time to Market：February 16, 2024.

Drug Introduction：On February 16, 2024, lifileucel (LN-144), developed by the American company Iovance Biotherapeutics, received accelerated approval from the U.S. FDA for the treatment of adult patients with unresectable or metastatic melanoma who have previously received PD-1 antibody therapy. This isThe World's First Marketed TIL Therapy, is expected to usher in a new era of solid tumor treatment!

Gastrointestinal Neuroendocrine Tumor

Lutathera

Drug Name：Lutathera（lutetium Lu 177 dotatate）。

R&D Company：Novartis.

Time to Market：April 23, 2024.

Drug Introduction：On April 23, 2024, Lutathera was approved by the U.S. FDA for the treatment of pediatric patients (≥12 years old) with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs, including foregut, midgut, and hindgut neuroendocrine tumors). This isFDA Approves First Radioactive Drug for SSTR-Positive GEP-NET Patients Aged 12 and Above。

Pediatric Low-Grade Glioma

tovorafenib

Drug Name：Tovorafenib (Ojemda).

R&D Company：Sunesis Pharmaceuticals。

Time to Market：April 23, 2024.

Drug Introduction：Tovorafenib is an orally administered pan-Raf kinase selective inhibitor. On April 23, 2024, Tovorafenib received accelerated approval from the U.S. FDA for the treatment of recurrent or refractory pediatric low-grade glioma (LGG) in patients aged 6 months and older who have BRAF fusions or rearrangements, or BRAF V600 mutations. This isFDA Approves First Systemic Therapy for Pediatric Low-Grade Glioma with BRAF Rearrangement (Including Fusions)。

Thyroid Cancer/Solid Tumor

Selpercatinib

Drug Name：Selpercatinib (Selpercatinib, Retevmo).

R&D Company：Eli Lilly and Company.

Time to Market：May 29, 2024.

Drug Introduction：On May 29, 2024, the U.S. FDA granted accelerated approval to Selpercatinib for the treatment of pediatric patients aged 2 years and older with metastatic thyroid cancer or solid tumors harboring RET mutations.FDA Approves First Targeted Therapy for Pediatric Patients Under 12 with RET MutationsPreviously, Selpercatinib had received accelerated approval for the treatment of adult solid tumors and thyroid cancer in adults and pediatric patients aged 12 years and older.

Urothelial Carcinoma

1. Urothelial Carcinoma - Erdafitinib

Drug Name：Erdafitinib (Erdafitinib, Balversa).

R&D Company：Janssen Biotech, Inc.

Time to Market：January 19, 2024.

Drug Introduction：Erdafitinib (Balversa) is an oral pan-FGFR inhibitor. On January 19, 2024, it was approved by the U.S. FDA for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) whose disease has progressed during or after at least one prior line of systemic therapy.

2. Urothelial Carcinoma - Nivolumab

Drug Name：Nivolumab (Opdivo, nivolumab, Odivo).

R&D Company：Bristol-Myers Squibb Company.

Time to Market：March 6, 2024.

Drug Introduction：Nivolumab (Opdivo) is a programmed death receptor-1 (PD-1) blocking antibody, which was approved by the U.S. FDA on March 6, 2024, for use in combination with cisplatin and gemcitabine as a first-line treatment for adult patients with unresectable or metastatic urothelial carcinoma.

Bladder Cancer

Anktiva

Drug Name：Anktiva（Altor BioScience，LLC，nogapendekin alfainbakicept-pmln）。

R&D Company：ImmunityBio.

Time to Market：April 22, 2024.

Drug Introduction：Anktiva is a potent immunostimulant that activates the body's natural immune system, unleashes antitumor activity, and promotes durable, complete responses. On April 22, 2024, the U.S. FDA approved Anktiva in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC).

Pediatric B-cell Acute Lymphoblastic Leukemia (B-ALL)

Inotuzumab Ozogamicin

Drug Name：Inotuzumab Ozogamicin (B esponsa, Inotuzumab Ozogamicin, Besponsa®).

R&D Company：Pfizer Inc.

Time to Market：March 6, 2024.

Drug Introduction：Inotuzumab Ozogamicin is a humanized antibody-drug conjugate targeting CD22. On March 6, 2024, Inotuzumab Ozogamicin was approved by the U.S. FDA for the treatment of relapsed or refractory CD22-positive B-cell precursors.

Adult Acute Lymphoblastic Leukemia

1. Adult Acute Lymphoblastic Leukemia - Ponatinib

Drug Name：Ponatinib (ponatinib, ICLUSIG®).

R&D Company：Takeda Pharmaceutical Company Limited.

Time to Market：March 19, 2024.

Drug Introduction：Ponatinib is a tyrosine kinase inhibitor (TKI). On March 19, 2024, the U.S. FDA granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adults with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.

2. Adult Acute Lymphoblastic Leukemia - Blinatumomab

Drug Name：blinatumomab（BLINCYTO®）。

R&D Company：Amgen Inc.

Time to Market：June 14, 2024.

Drug Introduction：On June 14, 2024, blinatumomab was approved by the U.S. FDA for the treatment of adult and pediatric patients ≥1 month old with CD19-positive Philadelphia chromosome-negative (Ph-negative) B-cell precursor acute lymphoblastic leukemia (BCP ALL). Notably,Blinatumomab is the first and only bispecific T-cell engager (BiTE®) therapy for consolidation treatment., regardless of the measurable minimal residual disease (MRD) status.

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Breyanzi

Drug Name：Breyanzi (lisocabtagene maraleucel, liso-cel).

R&D Company：Bristol-Myers Squibb Company.

Time to Market：March 15, 2024.

Drug Introduction：Breyanzi is a genetically modified autologous CAR-T cell therapy targeting CD19. On March 15, 2024, the U.S. FDA granted accelerated approval to Breyanzi for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received at least two lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

Mantle Cell Lymphoma

Breyanzi

Drug Name：Breyanzi (lisocabtagene maraleucel, liso-cel).

R&D Company：Bristol-Myers Squibb Company.

Time to Market：May 31, 2024.

Drug Introduction：Breyanzi was approved by the U.S. FDA on May 31, 2024, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior therapies, including one BTK inhibitor. This FDA approval also marksBreyanzi has become the most widely used CAR-T cell therapy for treating B-cell malignancies., which has been approved for the treatment of four different subtypes of non-Hodgkin lymphoma.。

Follicular Lymphoma

1. Follicular Lymphoma - Breyanzi

Drug Name：Breyanzi (lisocabtagene maraleucel, liso-cel).

R&D Company：Bristol-Myers Squibb Company.

Time to Market：May 15, 2024.

Drug Introduction：Breyanzi's Use Expanded to Another Type of Blood Cancer: On May 15, 2024, the U.S. FDA granted accelerated approval to Breyanzi for the treatment of relapsed or refractory follicular lymphoma (FL) patients who have previously received at least two lines of therapy.

2. Follicular Lymphoma - Zanubrutinib

Drug Name：Zanubrutinib (Zanubrutinib, Brukinsa).

R&D Company：BeiGene.

Time to Market：March 7, 2024.

Drug Introduction：On March 7, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib (Zanubrutinib) in combination with obinutuzumab (Obinutuzumab) for the treatment of relapsed or refractory follicular lymphoma (FL) in patients who have received two or more lines of systemic therapy. Notably,Zanubrutinib is the first and only BTK inhibitor approved for the treatment of follicular lymphoma.

3. Follicular Lymphoma - Epcoritamab

Drug Name：Epcoritamab（Epcoritamab-bysp，Epkinly）。

R&D Company：Genmab US,Inc。

Time to Market：June 26, 2024.

Drug Introduction：Epcoritamab-bysp is a bispecific CD3 T-cell engager (CD3/CD20 bispecific antibody) targeting CD20. On May 19, 2023, it received accelerated approval from the U.S. FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma and high-grade B-cell lymphoma after two or more lines of systemic therapy.

Multiple Myeloma

1. Multiple Myeloma - Abecma

Drug Name：Abecma（Idecabtagene vicleucel，ide-cel）。

R&D Company：Bristol-Myers Squibb/Bluebird Bio.

Time to Market：April 4, 2024.

Drug Introduction：Abecma is a CAR-T cell therapy that can recognize and bind to the BCMA antigen on the surface of multiple myeloma cells. It is worth mentioning that it isWorld's First Anti-BCMA CAR-T Cell TherapyOn March 26, 2021, it received FDA approval for the treatment of relapsed and refractory multiple myeloma. On April 4, 2024, the U.S. FDA approved the expanded use of Abecma for the treatment of multiple myeloma in adult patients with relapsed or refractory multiple myeloma who have previously received two or more lines of therapy [including immunomodulatory agents (IMiD), anti-CD38 monoclonal antibodies, and proteasome inhibitors (PI)].

2. Multiple Myeloma - Cilta-cel

Drug Name：Cilta-cel (Carvykti, cilta-cel).

R&D Company：Legend Biotech.

Time to Market：April 5, 2024.

Drug Introduction：Cilta-cel, developed through a collaboration between Janssen Innovative Pharmaceuticals and Legend Biotech, is a CAR-T therapy targeting BCMA (B-cell maturation antigen). In January 2023, the CDE granted priority review to the new drug application for this product. On April 5, 2024, cilta-cel received approval from the U.S. FDA for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM) who have previously received at least one prior line of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and are refractory to lenalidomide (Revlimid).

Solid Tumor

1. Solid Tumors - Trastuzumab Deruxtecan

Drug Name：Trastuzumab deruxtecan (T-DXd, DS-8201, Enhertu®).

R&D Company：AstraZeneca/Daiichi Sankyo Group.

Time to Market：April 5, 2024.

Drug Introduction：Trastuzumab Deruxtecan is a novel antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2). On April 5, 2024, the U.S. FDA granted accelerated approval to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have previously received systemic therapy and have no satisfactory alternative treatment options.Read the original article for more details: FDA Approval | The Magic Anti-Cancer Drug DS-8201 Available for All Cancer Types, Effective Against Dozens of HER2-Positive Cancers, Breaking Usage Restrictions

2. Solid Tumors - Ripretinib

Drug Name：Repotrectinib (Repotrectinib, code TPX-0005).

R&D Company：Bristol-Myers Squibb Company.

Time to Market：June 13, 2024.

Drug Introduction：Repotrectinib, developed in the United States, is a second-generation ALK/ROS1/TRK inhibitor and a new generation of broad-spectrum anticancer drug. On June 13, 2024, it received accelerated approval from the U.S. FDA for the treatment of solid tumors positive for neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as well as locally advanced, metastatic, or solid tumors where surgical resection may lead to severe morbidity. It is indicated for adult and pediatric patients (≥12 years old) whose disease has progressed after treatment or who have no satisfactory alternative therapies.

Editor's Note

The above-mentioned new drugs are only a small part of the many research and development hotspots. There are also numerous new drug developments and innovative technologies on the way. It is believed that there will be more drug approvals in the second half of 2024! In addition, several anticancer drugs under development have also shown broad-spectrum anticancer capabilities. The "Ark Aid Program" can provide patients with the opportunity for free treatment using newly approved or yet-to-be-approved drugs. With the continuous advancement of medical research, it is believed that an increasing number of new drugs will be developed and launched, allowing more patients to surpass one five-year milestone after another!

References

[1] U.S. FDA Official Website

https://www.fda.gov/

[2] China NMPA Official Website

https://www.nmpa.gov.cn/

#Ark Gene Treasure Plan#

"Ark Gene Treasure Plan" is a gene "treasure hunt" initiative launched by Global Cancer Doctors Network in collaboration with Cancer-Free Home, authoritative gene testing institutions, international pharmaceutical companies, and renowned cancer centers. This plan aims to thoroughly explore the survival hope indicated in each gene testing report, comprehensively interpret the gene testing reports for cancer patients, and match cancer patients with suitable marketed new drugs and clinical trials of investigational drugs on a global scale, seeking new survival opportunities as well as chances for free treatment with marketed or unmarketed new drugs!

Patients who wish to participate can send their genetic test reports and diagnostic reports electronically.Subsidiary or AcquisitionIlluminateSend to: doctor.huang@globecancer.com. Leave contact information in the email, and the Medical Department will contact you by phone within 1 working day after receiving and analyzing the report; or call directly.Global Oncology Doctors Network Medical Department (400-666-7998)Evaluation.

This article is original from Global Oncologist Network. Reproduction is strictly prohibited without authorization.

Scan to Add Patient Group

Cancer Fighting News｜New Technologies｜New Drug Development｜Authoritative Experts

Join the group to receive free anti-cancer resources